Changing Patterns in Clinicopathological Characteristics of Breast Cancer and Prevalence of BRCA Mutations: Analysis in a Rural Area of Southern China

References

• Li H, Zheng RS, Zhang SW, et al. Incidence and mortality of female breast cancer in China, 2014. Chin J Oncol. 2018;40(3):166–171.
   Google Scholar
• Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Chin J Oncol. 2019;41(1):19–28.
   Google Scholar
• Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–e289. doi:10.1016/S1470-2045(13)70567-9
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003–2005: a population-based study. Int J Cancer. 2015;136(8):1921–1930. doi:10.1002/ijc.29227
   PubMed Web of Science ®Google Scholar
• Newman LA. Breast cancer disparities: socioeconomic factors versus biology. Ann Surg Oncol. 2017;24(10):2869–2875. doi:10.1245/s10434-017-5977-1
   PubMed Web of Science ®Google Scholar
• Williams F, Jeanetta S, James AS. Geographical location and stage of breast cancer diagnosis: a systematic review of the literature. J Health Care Poor Underserved. 2016;27(3):1357–1383. doi:10.1353/hpu.2016.0102
   PubMed Web of Science ®Google Scholar
• Samilia OG, Lava T, Oindrila B, et al. Breast cancer presentation, surgical management and mortality across the rural-urban continuum in the national cancer database. Ann Surg Oncol. 2020;27(6):1805–1815. doi:10.1245/s10434-020-08376-y
   PubMed Web of Science ®Google Scholar
• McCullough LE, Flowers CR. Identifying and addressing disparities in survival outcomes for rural patients with cancer. JAMA Netw Open. 2018;1(4):e181243. doi:10.1001/jamanetworkopen.2018.1243
   PubMed Web of Science ®Google Scholar
• Jubair S, Alkhateeb A, Abou Tabl A, et al. A novel approach to identify subtype-specific network biomarkers of breast cancer survivability. Netw Model Anal Health Inform Bioinform. 2020;9(1):43. doi:10.1007/s13721-020-00249-4
   Web of Science ®Google Scholar
• Kwong A, Shin VY, Ho JC, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet. 2016;53(1):15–23. doi:10.1136/jmedgenet-2015-103132
   PubMed Web of Science ®Google Scholar
• Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628–663. doi:10.1038/s41591-018-0009-7
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Kim EK, Park SY, Kim SW. Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients. J Pathol Transl Med. 2020;54(4):265–275. doi:10.4132/jptm.2020.04.07
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Chan DSM, Abar L, Cariolou M, et al. World Cancer Research Fund International: continuous update project-systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes Control. 2019;30(11):1183–1200.
   PubMed Web of Science ®Google Scholar
• Ellingjord-Dale M, Vos L, Tretli S, et al. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Res. 2017;19(1):10. doi:10.1186/s13058-016-0798-x
   PubMed Web of Science ®Google Scholar
• Leso V, Ercolano ML, Cioffi DL, et al. Occupational chemical exposure and breast cancer risk according to hormone receptor status: a systematic review. Cancers (Basel). 2019;11(12):E1882. doi:10.3390/cancers11121882
   PubMed Web of Science ®Google Scholar
• White AJ, DeRoo LA, Weinberg CR, et al. Lifetime alcohol intake, binge drinking behaviors, and breast cancer risk. Am J Epidemiol. 2017;186(5):541–549. doi:10.1093/aje/kwx118
   PubMed Web of Science ®Google Scholar
• Gao Y, Huang Y, Song F, et al. Urban-rural disparity of overweight/obesity distribution and its potential trend with breast cancer among Chinese women. Oncotarget. 2016;7(35):56608–56618. doi:10.18632/oncotarget.10968
   PubMedGoogle Scholar
• Wen D, Wen X, Yang Y, et al. Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting. Thorac Cancer. 2018;9(2):262–272. doi:10.1111/1759-7714.12575
   PubMed Web of Science ®Google Scholar
• Kang SY, Kim YS, Kim Z, et al. Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry. J Breast Cancer. 2018;21(1):1–10. doi:10.4048/jbc.2018.21.1.1
   PubMed Web of Science ®Google Scholar
• Lin WZ, Lin YC, Zeng D, et al. Clinical and pathological features of 1920 patients with breast cancer in Chaoshan area. Chin J Cancer Prev Treat. 2009;16(24):1905–1908.
   Google Scholar
• Linghu RX, Si W, Li Y. Epidemiological and clinicopathological characteristics of patients with breast cancer: a retrospective analysis of 3 846 case. Acad J PLA Postgrad Med Sch. 2015;36(10):1017–1021.
   Google Scholar
• Nakamura K, Okada E, Ukawa S, et al. Characteristics and prognosis of Japanese female breast cancer patients: the BioBank Japan project. J Epidemiol. 2017;27(3S):S58–S64.
   PubMed Web of Science ®Google Scholar
• Argolo DF, Hudis CA, Iyengar NM. The impact of obesity on breast cancer. Curr Oncol Rep. 2018;20(6):47. doi:10.1007/s11912-018-0688-8
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou B, Zhao Z, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18. Lancet. 2021;398(10294):53–63. doi:10.1016/S0140-6736(21)00798-4
   PubMed Web of Science ®Google Scholar
• Park B, Choi JY, Sung HK, et al. Attribution to heterogeneous risk factors for breast cancer subtypes based on hormone receptor and human epidermal growth factor 2 receptor expression in Korea. Medicine (Baltimore). 2016;95(14):e3063. doi:10.1097/MD.0000000000003063
   PubMed Web of Science ®Google Scholar
• Gao X, Nan X, Liu Y, et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Hum Mutat. 2020;41(3):696–708. doi:10.1002/humu.23965
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang H, Wang X, et al. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort. J Hematol Oncol. 2021;14(1):18. doi:10.1186/s13045-020-01010-0
   PubMed Web of Science ®Google Scholar
• Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80. doi:10.1007/s10549-015-3293-7
   PubMed Web of Science ®Google Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405. doi:10.1056/NEJMoa2105215
   PubMed Web of Science ®Google Scholar
• Schettini F, Corona SP, Giudici F, et al. Clinical, radiometabolic and immunologic effects of olaparib in locally advanced triple negative breast cancer: the OLTRE window of opportunity trial. Front Oncol. 2021;11:686776.
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240–249. doi:10.1016/j.annonc.2020.11.009
   PubMed Web of Science ®Google Scholar